This webinar will summarize the Sunshine Act or Open Payments Program requirements and provide practical solutions to the most common situations that are prevalent and necessary between sponsors and investigators.
The Sunshine Act or Open Payments Program requires manufacturers of drugs, medical devices, and biologics that participate in U.S. federal health care programs to report certain clinical investigator payments and items of value given to physicians and teaching hospitals. This Act was part of a healthcare reform bill adopted in March 2010. It came about due to requests for increased transparency about the financial relationships between physicians and the industry.
The Sunshine Act exposes the physicians and sponsors to new clinical trial reporting requirements and detail non-compliance which would lead to hefty fines. Templates for reporting format, exemptions to reporting requirements, and timelines for compliance and enforcement will be discussed.
Life science companies face the challenge of implementing the detailed reporting required by the Act as healthcare providers determine how to use their own data to anticipate public reporting of payments by life science companies to physicians and teaching hospitals.
This webinar will examine the implications of the Sunshine Act for healthcare providers and life science companies and discuss practical steps they can take to implement the Act and prepare for transparency.
The Sunshine Act exposes the physicians and sponsors to new clinical trial reporting requirements and detail non-compliance which would lead to hefty fines. Templates for reporting format, exemptions to reporting requirements, and timelines for compliance and enforcement will be discussed.
Life science companies face the challenge of implementing the detailed reporting required by the Act as healthcare providers determine how to use their own data to anticipate public reporting of payments by life science companies to physicians and teaching hospitals.
This webinar will examine the implications of the Sunshine Act for healthcare providers and life science companies and discuss practical steps they can take to implement the Act and prepare for transparency.
Danielle DeLucy
Danielle DeLucy, MS, is owner of ASA Training and Consulting, LLC which provides Pharmaceutical and Biologics based companies with training and quality systems assistance in order to meet Regulatory compliance. Prior to this role, Danielle has been in the industry for 15 years serving in numerous Quality Management Roles, such as the Director of Product Quality, the oversight of Sterility Assurance practices and provided QA oversight of numerous filling and packaging operations. Danielle began her QA career as a Quality Control Pharmaceutical Microbiologist at a contract laboratory where she performed various tests for their clients. In the years after, she …
50+ new Excel features so far this decade
Mindful Communication:The Key to Meaningful Conversations i…
FMLA Compliance in 2025: A Comprehensive Guide & Strategies…
Excel - 10 Key Worksheet Functions to Skyrocket Your Produc…
Managing Toxic Employees: Strategies For Leaders To Effecti…
Hiring and Retaining Employees in this Crazy Economy
Harassment, Bullying, Gossip, Confrontational and Disruptiv…
Project Management for administrative professionals
Excel Power Skills: Master Functions, Formulas, and Macros …
Outlook - Master your Mailbox - Inbox Hero Inbox Zero
Copilot and HR: An Introduction for HR Professionals
California Meal and Rest Breaks: What You Don't Know Can Co…
Bootcamp for New Managers and Supervisors: Develop These Es…
Policy Pops: Navigating DEI in the 2025 Workplace: Strategi…
Emotional Intelligence: Mastering the Emotions of Great Lea…
How To Conduct An Internal Harassment And Bullying Investig…
How to Manage the Legal Landmine of the FMLA, ADA and Worke…
The Importance of the first 5 seconds when presenting
Managing Difficult Employee Conversations
Female to Female Hostility @Workplace: All you Need to Know
How to Write Effective Audit Observations: The Principles f…
FDA Proposes Framework to Advance Credibility of AI Models